Defibrotide News and Research

RSS

EBMT honours abstract on Defibrotide in Hepatic VOD prevention with the Van Bekkum Award

Gentium S.p.A. today announced that the abstract titled, "Defibrotide prevents hepatic VOD and reduces significantly VOD-associated complications in children at high risk: final results of a prospective phase II/III multicentre study," has been awarded the Van Bekkum Award for the best abstract submitted to the physician's program for the European Group for Blood and Marrow Transplantation's (EBMT) 36th Annual Meeting, to be held in Vienna, March 21-24, 2010.

5 Feb 2010

Gentium presents evaluation results of Defibrotide for VOD at the ASH conference

Gentium S.p.A. today announced final clinical trial results from the Company’s Phase II/III Pediatric Prevention trial and Phase III Treatment trial for Defibrotide of Hepatic Veno-Occlusive Disease (VOD), which were presented at the American Society of Hematology Conference (ASH) in New Orleans.

8 Dec 2009

Defibrotide drug effective against hepatic veno-occlusive disease

Defibrotide, a novel drug which modulates the response of blood vessels to injury, was markedly more effective than standard treatment in post-stem cell transplant patients with hepatic veno-occlusive disease, a life threatening toxicity of transplant caused by blockages in tiny blood vessels of the liver, according to a study led by Dana-Farber Cancer Institute scientists.

8 Dec 2009

Gentium announces financial results for the third quarter ended September 30, 2009

Gentium S.p.A. today reported financial results for the quarter ended September 30, 2009.

30 Nov 2009

Gentium to present Defibrotide trial data at the ASH meeting

Gentium S.p.A. announced today that results from the Company’s Phase II/III Pediatric Prevention trial and Phase III Treatment trial for Defibrotide of Hepatic Veno-Occlusive Disease will be presented at American Society of Hematology Conference (ASH), December 5-8 in New Orleans.

16 Nov 2009

Second-quarter fiscal 2009 results announced by Gentium

Gentium S.p.A. (NASDAQ: GENT) today reported financial results for the second quarter ended June 30, 2009.

17 Sep 2009

Gentium reports results from phase 3 trial of defibrotide for severe veno-occlusive disease

Gentium S.p.A. has announced top-line results from a historically controlled, multicenter, open label, Phase III trial designed to evaluate the safety and efficacy of 25 mg/kg/day of Defibrotide for the treatment of severe veno-occlusive disease (sVOD) in hematopoietic stem cell transplant (SCT) patients.

19 Aug 2009

Gentium S.p.A. updates on phase 3 trial of Defibrotide for severe veno-occlusive disease

Gentium S.p.A. announced today interim results from an independent Data Safety Monitoring Board (DSMB) review of the Company's Phase 3 treatment trial of Defibrotide for Severe Veno-Occlusive Disease (VOD).

19 Nov 2008

Defibrotide News and Research

EBMT honours abstract on Defibrotide in Hepatic VOD prevention with the Van Bekkum Award

Gentium presents evaluation results of Defibrotide for VOD at the ASH conference

Defibrotide drug effective against hepatic veno-occlusive disease

Gentium announces financial results for the third quarter ended September 30, 2009

Gentium to present Defibrotide trial data at the ASH meeting

Second-quarter fiscal 2009 results announced by Gentium

Gentium reports results from phase 3 trial of defibrotide for severe veno-occlusive disease

Gentium S.p.A. updates on phase 3 trial of Defibrotide for severe veno-occlusive disease

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News